RxDoctor Payments Data

Joseph Sappington, MD

Cardiovascular Disease · Glastonbury, CTNPI 1285629410

Payments from drug & device makers

$8,768in general payments, 2019–2025

Across 140 payments — averaging $62.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • AstraZeneca$388
  • Novartis$370
  • E.r. Squibb & Sons, L.L.C.$357
  • Johnson & Johnson$296
  • Pfizer$275
  • plus $758 from 13 others

What the payments were for

  • Travel & lodging$5,95968%
  • Food & beverage$2,78332%
  • Education$260%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,768 in reported general payments places this provider in the 75th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$55,668
Medicare patients
170
Services billed
626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban226$320,754
EntrestoSacubitril/Valsartan66$91,194
XareltoRivaroxaban52$86,995
BrilintaTicagrelor13$16,300
FarxigaDapagliflozin Propanediol12$10,464
Metoprolol Succinate329$4,056
Atorvastatin Calcium338$3,625
ClopidogrelClopidogrel Bisulfate285$3,097
Ranolazine ErRanolazine26$2,163
Metoprolol Tartrate302$2,119
Losartan Potassium201$1,969
Amlodipine Besylate251$1,957
Diltiazem 24hr Er (Cd)Diltiazem Hcl19$1,851
Nebivolol Hcl19$1,780
Furosemide212$1,374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$275$320,754226 claims
NovartisEntresto$370$91,19466 claims
Johnson & JohnsonXarelto$296$86,99552 claims
AstraZenecaBrilinta, Farxiga$388$26,76425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Glastonbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →